Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Assessing the true cost of infusion care: Comparing hospital chargemaster, cash, and negotiated prices for infusion CPT codes across top-ranked US hospitals.

Mason Nicholas Alford-Holloway, Austin Triana, Katherine Baker et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23186

e23186 Background: Patients in the United States often lack clear, actionable information about the prices of common outpa...

Length of stay, costs, and mortality in colon cancer: A regional comparison between the northeast and west.

Shruthi Sridhar, Daniel Cruceta Reynoso, Cesar O. Ortiz Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13756

e13756 Background: Colorectal cancer is a leading cause of cancer-related mortality in the United States, with an estimate...

Plasma cell-free chromatin state kinetics as a predictor of early treatment response in gastric cancer.

Xubin Chen, Yinkui Wang, Ziyu Li et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16073

e16073 Background: Early and reliable assessment of treatment response across heterogeneous gastric cancer (GC) regimens r...

HMA plus venetoclax for 7- vs 14- vs 21- vs 28-day cycles in newly-diagnosed acute myeloid leukemia: ELN- and Mayo Genetic Risk–stratified analysis in 540 patients.

Sudhesh Kumar, Momna Warraich, Mahnoor Fatima et al. Jun 01, 2026 pp. 6525-6525 10.1200/jco.2026.44.16_suppl.6525

6525 Background: Venetoclax plus hypomethylating agent (Ven-HMA) is the standard treatment for unfit patients with newly d...

PREDICT-RD: Postoperative molecular residual disease by ctDNA surveillance in TNBC with residual disease (TBCRC-071).

Yara Abdou, Naim Rashid, Katherine Elizabeth Reeder-Hayes et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps647

TPS647 Background: Patients with residual triple-negative breast cancer (TNBC) post-neoadjuvant therapy, particularly thos...

Clinical and structural factors associated with access to stereotactic body radiation therapy (SBRT) in lung cancer.

Amber Akhter, Ajit Venkatakrishnan, Apurva Mallisetty et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20104

e20104 Background: Stereotactic body radiation therapy (SBRT) is an established treatment modality for select patients wit...

Integrating genomics, imaging, and clinical data for late-onset cardiomyopathy prediction in pediatric cancer survivors: A multi-modal machine-learning comparison using St. Jude Cloud.

Masab Mansoor Jun 01, 2026 pp. 10018-10018 10.1200/jco.2026.44.16_suppl.10018

10018 Background: Pediatric cancer survivors face substantial risk of anthracycline- and radiation therapy (RT)-related ca...

Zirconium-engineered nanoplatform to enhance radiotherapy through NOD-like receptor-mediated pyroptosis.

Ling Du, Lei Wang Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14595

e14595 Background: Radiotherapy faces significant challenges in clinical application due to tumor radioresistance and pote...

Complex segmentectomy versus lobectomy in small-sized peripheral non–small cell lung cancer: A post-hoc supplemental analysis of a multicenter, open-label, phase 3 trial (JCOG0802/WJOG4607L).

Atsushi Kamigaichi, Takahiro Mimae, Ryu Nakajima et al. Jun 01, 2026 pp. 8009-8009 10.1200/jco.2026.44.16_suppl.8009

8009 Background: JCOG0802/WJOG4607L confirmed the superiority of segmentectomy on overall survival (OS) over lobectomy for...

Impact of outpatient CAR T-cell therapy administration on healthcare utilization in patients with hematologic malignancies.

Susanna Goggans Bowen, Nadine Abdallah, Joshua C. Pritchett et al. Jun 01, 2026 pp. 1503-1503 10.1200/jco.2026.44.16_suppl.1503

1503 Background: CAR T-cell therapy has revolutionized treatment outcomes in hematological malignancies, but has tradition...

Racial disparities in maternal outcomes among pregnant patients with cancer: A National Inpatient Sample analysis.

Lawin Steve Mathew Lasington, Jeril Lasington, Swamynathan Umamaheswaran Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23244

e23244 Background: Pregnancy-associated cancer affects approximately 1 in 1,000 pregnancies. We conducted a national analy...

Overall survival benefit of doublet versus triplet BRAF inhibitor–based therapy: Insights from the BEETS study (JACCRO CC-18).

Chiaki Inagaki, Ryo Matoba, Eisuke Inoue et al. Jun 01, 2026 pp. 3540-3540 10.1200/jco.2026.44.16_suppl.3540

3540 Background: Cetuximab plus encorafenib, with or without binimetinib, is established as one of the standard treatment...

Effect of higher initial dose and accelerated titration of ropeginterferon alfa-2b on early hematologic and molecular responses in polycythemia vera: A meta-analysis.

Abdulraheem Yacoub, Shinya Imada, Chun-Ting Wu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18592

e18592 Background: Ropeginterferon alfa-2b (ropeginterferon) is a mono-pegylated interferon-alpha that received FDA approv...

Real-world outcomes of microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) biliary tract cancers (BTC).

Madhulika Eluri, Andrés J. Muñoz Martín, Lianchun Xiao et al. Jun 01, 2026 pp. 4128-4128 10.1200/jco.2026.44.16_suppl.4128

4128 Background: Immune checkpoint inhibitors have revolutionized the treatment of microsatellite instability–high (MSI-H)...

Sociodemographic disparities in cervical cancer incidence, mortality, and disability-adjusted life years in Europe, 1990-2023.

Muhammad Huzaifa Khalil, Syed Mohamin Abbas Shah, Muhammad Abbas Khokhar et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17520

e17520 Background: Cervical cancer remains a public health concern in Europe despite effective prevention strategies, incl...

Progressive locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients treated with donafenib: A real-world study.

Panli Li, Zerong Wang, Fei Liu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18018

e18018 Background: Donafenib was approved for the treatment of RAI-R DTC patients by National Medical Products Administrat...

Concomitant radiotherapy, tremelimumab, and durvalumab for advanced NSCLC patients progressing on first-line immunotherapy: A phase 2 study (CORAL-Lung).

Jair Bar, Hadas Gantz Sorotsky, Damien Urban et al. Jun 01, 2026 pp. 8583-8583 10.1200/jco.2026.44.16_suppl.8583

8583 Background: The optimal treatment for advanced NSCLC that developed resistance to immune checkpoint inhibitors (CPIs)...

Non-random patterns of multiple primary malignancies in the era of cancer survival.

Thomas George, Kaelyn Nannini, John R. Bihn et al. Jun 01, 2026 pp. 10584-10584 10.1200/jco.2026.44.16_suppl.10584

10584 Background: Improved cancer therapies have increased survival, placing survivors at risk for subsequent primary canc...

Results of peripheral blood immune analysis in patients receiving immune checkpoint inhibitor therapy and correlation with immune-related adverse events.

Upendra P. Hegde, Ursula Medeiros Araujo de Matos, Phil Kerr et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19568

e19568 Background: Immune-related adverse events (irAEs) result from T-lymphocyte activation induced by immune checkpoint...

Real-world patterns of PD-L1 expression, biomarker testing, and immunotherapy utilization across lung and other solid tumors in an Asian cohort.

Jugnu Jain, Navya Dasari, Syed M. Hussaini et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23380

e23380 Background: Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) is an established enrichment biomarker gui...

An AI-enabled framework for pre-visit decision support using patient similarity analysis in melanoma.

Svetomir Markovic Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21533

e21533 Background: Clinical decision-making in melanoma is challenged by heterogeneous disease biology, evolving treatment...

A multi-institutional epidemiologic and oncologic profile of gastrointestinal stromal tumors in the Lebanese population.

Mohamad Hadi El Charif, Eman Samih Sbaity, Mohamad Ali Salloum et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23508

e23508 Background: Gastrointestinal stromal tumor (GIST) is a rare type of soft tissue sarcoma that most commonly arises f...

Pan-cancer multi-omic integration for identification of clinically aggressive and potentially actionable molecular modules in breast, endometrial, and ovarian cancers.

Sandra Lorena Romero-Cordoba, Dominique Cortés-Pedroza Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12610

e12610 Background: Pan-cancer analysis enable the detection of molecular alterations that are individually infrequent with...

Precision oncology in practice: Real-world multicenter experience with larotrectinib in pediatric extracranial NTRK fusion–positive tumors.

Rejin Kebudi, Miray Yildirim, Gulsah E. Tanyildiz et al. Jun 01, 2026 pp. 10036-10036 10.1200/jco.2026.44.16_suppl.10036

10036 Background: Gene fusions involving NTRK1/2/3 represent actionable oncogenic...

Endometrial cancer mortality among postmenopausal women in the United States, 1999-2023.

Haneen Asma, Vishan Das, Kaneez Fatima et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17621

e17621 Background: Endometrial cancer occurs predominantly in postmenopausal women, driven by hormonal imbalance and metab...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page